| An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer A Davies, S Nouruzi, D Ganguli, T Namekawa, D Thaper, S Linder, ... Nature cell biology 23 (9), 1023-1034, 2021 | 114 | 2021 |
| Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond S Linder, HG van der Poel, AM Bergman, W Zwart, S Prekovic Endocrine-related cancer 26 (1), R31-R52, 2019 | 72 | 2019 |
| Optimized ChIP-seq method facilitates transcription factor profiling in human tumors AA Singh, K Schuurman, E Nevedomskaya, S Stelloo, S Linder, M Droog, ... Life science alliance 2 (1), 2019 | 53 | 2019 |
| Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence S Linder, M Hoogstraat, S Stelloo, N Eickhoff, K Schuurman, H de Barros, ... Cancer discovery 12 (9), 2074-2097, 2022 | 49 | 2022 |
| Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division ARR Maia, S Linder, JY Song, C Vaarting, U Boon, CEJ Pritchard, A Velds, ... British Journal of Cancer 118 (12), 1586-1595, 2018 | 45 | 2018 |
| Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer T Bernasocchi, G El Tekle, M Bolis, A Mutti, A Vallerga, LP Brandt, ... Nature communications 12 (1), 734, 2021 | 39 | 2021 |
| Molecular underpinnings of enzalutamide resistance S Prekovic, T Van den Broeck, S Linder, ME van Royen, AB Houtsmuller, ... Endocrine-related cancer 25 (11), R545-R557, 2018 | 38 | 2018 |
| Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation SC Baca, C Singler, S Zacharia, JH Seo, T Morova, F Hach, Y Ding, ... Nature genetics 54 (9), 1364-1375, 2022 | 34 | 2022 |
| Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer MD Long, JJ Jacobi, PK Singh, G Llimos, SA Wani, AM Rowsam, ... Cell reports 37 (11), 2021 | 28 | 2021 |
| Functional mapping of androgen receptor enhancer activity CCF Huang, S Lingadahalli, T Morova, D Ozturan, E Hu, IPL Yu, S Linder, ... Genome biology 22 (1), 149, 2021 | 23 | 2021 |
| Transposable elements are co-opted as oncogenic regulatory elements by lineage-specific transcription factors in prostate cancer G Grillo, T Keshavarzian, S Linder, C Arlidge, L Mout, A Nand, M Teng, ... Cancer discovery 13 (11), 2470-2487, 2023 | 14 | 2023 |
| A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated … SAL Palit, J van Dorp, D Vis, C Lieftink, S Linder, R Beijersbergen, ... Scientific reports 11 (1), 13683, 2021 | 14 | 2021 |
| Radiogenomics analysis linking multiparametric MRI and transcriptomics in prostate cancer C Dinis Fernandes, A Schaap, J Kant, P van Houdt, H Wijkstra, E Bekers, ... Cancers 15 (12), 3074, 2023 | 10 | 2023 |
| Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program S Stelloo, S Linder, E Nevedomskaya, E Valle-Encinas, I de Rink, ... Endocrine-related cancer 27 (2), 67-79, 2020 | 10 | 2020 |
| Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs S Linder, TM Severson, KJC van der Mijn, E Nevedomskaya, JC Siefert, ... European Urology 84 (5), 455-460, 2023 | 7 | 2023 |
| Unexpected gene activation following CRISPR‐Cas9‐mediated genome editing AG Manjón, S Linder, H Teunissen, A Friskes, W Zwart, E de Wit, ... EMBO reports 23 (2), e53902, 2022 | 7 | 2022 |
| Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients TM Severson, Y Zhu, S Prekovic, K Schuurman, HM Nguyen, LG Brown, ... medRxiv, 2023.02. 24.23286403, 2023 | 3 | 2023 |
| Compartmentalization of androgen receptors at endogenous genes in living cells S Yavuz, H Kabbech, J van Staalduinen, S Linder, WA van Cappellen, ... Nucleic Acids Research 51 (20), 10992-11009, 2023 | 2 | 2023 |
| Abstract B041: AR suppresses MHC Class I expression and T-cell response in prostate cancer L Chesner, J Graff, F Polesso, A Smith, A Lundberg, M Sjoestroem, Z Xia, ... Cancer Research 83 (11_Supplement), B041-B041, 2023 | 2 | 2023 |
| AR inhibition increases MHC class I expression and improves immune response in prostate cancer LN Chesner, JN Graff, F Polesso, A Smith, A Lundberg, R Das, T Shenoy, ... | 2 | 2023 |
